Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Lizette Alvarez

Physical Medicine & Rehabilitation Saint Louis, MO Medical Doctor

NPI 1750342580 CMS profile 306756

3009 N Ballas Rd, Suite 323A, Saint Louis, MO 63131

Open in the dashboard

General payments

$182,400

1,238 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Lizette Alvarez of Saint Louis, MO is reported in the CMS Open Payments database as having received $182,400 across 1,238 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Physical Medicine & Rehabilitation profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $11,390 141
2024 General $19,485 149
2023 General $9,077 174
2022 General $11,461 187
2021 General $52,226 222
2020 General $23,321 185
2019 General $55,441 180

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lizette Alvarez
  • Physical Medicine & Rehabilitation median
  • Middle half of Physical Medicine & Rehabilitation
  • National median

In program year 2025, general payments to Lizette Alvarez were reported at $11,390. Among 4,146 Physical Medicine & Rehabilitation profiles paid that year, the median was $139 and the middle half received between $48 and $410.

Show as a table
Year Lizette Alvarez Physical Medicine & Rehabilitation median Middle half National median
2019 $55,441 $133 $45–$390 $163
2020 $23,321 $88 $29–$272 $114
2021 $52,226 $116 $33–$360 $132
2022 $11,461 $123 $40–$378 $149
2023 $9,077 $131 $43–$396 $160
2024 $19,485 $141 $45–$409 $164
2025 $11,390 $139 $48–$410 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Allergan Inc. $119,548 364 payments
  2. AbbVie, Inc. $40,044 379 payments
  3. Piramal Critical Care $10,967 50 payments
  4. Merz North America, Inc. $3,548 18 payments
  5. Ipsen Biopharmaceuticals, Inc $1,905 116 payments
  6. Merz Pharmaceuticals, LLC $1,485 58 payments
  7. Avanir Pharmaceuticals, Inc. $1,133 63 payments
  8. Pfizer Inc. $744 45 payments
  9. Medtronic, Inc. $487 12 payments
  10. Otsuka America Pharmaceutical, Inc. $462 17 payments
  11. Other $2,076 116 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $136,925 64 payments
  2. Food and Beverage $25,269 1,140 payments
  3. Consulting Fee $7,865 5 payments
  4. Travel and Lodging $5,108 12 payments
  5. Honoraria $4,650 2 payments
  6. Compensation for serving as faculty or as a speaker for a medical education program $2,486 2 payments
  7. Education $97 13 payments
Products named General payments · program years 2019–2025
  1. BOTOX Neuroscience $82,412 81 payments
  2. BOTOX Neuroscience $47,544 48 payments
  3. GABLOFEN Pharmacology $8,172 36 payments
  4. GABLOFEN Pharmacology $8,172 36 payments
  5. GABLOFEN Pharmacology $8,172 36 payments
  6. GABLOFEN Pharmacology $8,172 36 payments
  7. UBRELVY Neuroscience $7,385 41 payments
  8. BOTOX Botox Therapeutic $5,831 164 payments
  9. UBRELVY Neuroscience $5,049 98 payments
  10. Xeomin $4,450 53 payments
  11. Other $19,638 827 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 25 drugs

Part D claims

967

Median for Physical Medicine and Rehabilitation: 276

Drug cost

$107,558

Median for Physical Medicine and Rehabilitation: $5,921

Branded share of claims

8.6%

Median for Physical Medicine and Rehabilitation: 11.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Nuedexta Dextromethorphan Hbr/Quinidine Brand 40 $65,904
Eliquis Apixaban Brand 43 $23,645
Baclofen Generic 276 $7,015
Gabapentin Generic 72 $1,865
Amiodarone Hcl Generic 11 $1,503
Duloxetine Hcl Generic 42 $1,250
Pregabalin Generic 34 $1,216
Methylphenidate Hcl Generic 50 $1,204
Tizanidine Hcl Generic 65 $1,010
Diazepam Generic 56 $624

The 10 drugs with the highest cost, of 25 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,591 Part D prescribers listed as Physical Medicine and Rehabilitation; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 35 billing codes

Paid by Medicare

$1,269,233

Of which drugs: $1,080,317

Medicare patients

304

Average age 66

Services billed

213,873

159 women, 145 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 68%
Arthritis 52%
Depression 48%
Ischemic heart disease 28%
Chronic kidney disease 24%
Osteoporosis 24%
Diabetes 23%
Heart failure 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, onabotulinumtoxina, 1 unit J0585 Office 124 155,500 $759,913
Injection, incobotulinumtoxin a, 1 unit J0588 Office 50 53,900 $219,104
Injection, baclofen, 10 mg J0475 Office 37 754 $91,853

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BOTOX
$12,724 — 155,500
GABLOFEN
$5,041 — 754
DYSPORT
$472 — —
Xeomin
$269 — 53,900
ZAVZPRET
$184 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

1,238 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physical Medicine & Rehabilitation in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record